{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:02:16Z","timestamp":1777006936503,"version":"3.51.4"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review aims to provide updated information about myasthenia gravis (MG) complicated with autoimmune encephalitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MG and autoimmune encephalitis are both antibody-mediated disorders with a need for active and individually adapted immunosuppressive treatment. The two disorders can co-exist. This represents therapeutic and diagnostic challenges but may help in elucidating disease mechanisms and risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search combined the words \u201cmyasthenia gravis,\u201d \u201cautoimmune encephalitis,\u201d and further combined each specific antibody associated with autoimmune encephalitis and \u201cmyasthenia gravis.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Epidemiological data and multiple single case reports illustrate the increased risk for autoimmune encephalitis in MG. The target antigens for the antibodies in both MG and autoimmune encephalitis vary among patients. Clinical manifestations, choice of therapy, and prognosis depend on antibody pattern. MG should be treated actively with immunosuppression according to updated and generally accepted guidelines. For treatment of autoimmune encephalitis, high corticosteroid doses, intravenous immunoglobulin (IVIg), plasma exchange, and rituximab should be considered. FcRn-blockers represent an additional option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MG and autoimmune encephalitis have overlapping pathogenesis and similar preferred drug therapies. This comorbidity represents a therapeutic challenge, and often with the need of high-dose immunosuppressive combination therapy. New and targeted therapies are applied in some MG patients, and such therapies have relevance also for autoimmune encephalitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1812305","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:30:14Z","timestamp":1777005014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia gravis complicated with autoimmune encephalitis: a review"],"prefix":"10.3389","volume":"17","author":[{"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen","place":["Bergen, Norway"]},{"name":"Department of Neurology, Haukeland University Hospital","place":["Bergen, Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/nejmra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/bs.irn.2025.04.028","article-title":"Epidemiology of myasthenia gravis","volume":"182","author":"Gilhus","year":"2025","journal-title":"Int Rev Neurobiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2015","journal-title":"Eur J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00650-1","article-title":"Autoimmune encephalitis","volume":"11","author":"de Bruijn","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.neuron.2024.12.006","article-title":"Toward curing neurological autoimmune disorders biomarkers, immunological mechanisms, and therapeutic targets","volume":"113","author":"Segal","year":"2025","journal-title":"Neuron"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e16229","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/pn-2025-004655","article-title":"Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)","volume":"25","author":"Jacob","year":"2025","journal-title":"Pract Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e14568","DOI":"10.1111\/cns.14568","article-title":"Thymoma-associated autoimmune encephalitis with myasthenia gravis: case series and literature review","volume":"30","author":"Su","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1212\/01.WNL.0000050461.05432.C5","article-title":"Myasthenia gravis -: a higher than expected incidence in the elderly","volume":"60","author":"Aragon\u00e8s","year":"2003","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/ene.12439","article-title":"Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study","volume":"21","author":"Andersen","year":"2014","journal-title":"Eur J Neurol"},{"key":"ref14","article-title":"Changes in myasthenia gravis incidence in Denmark from 1985 to 2021 a nationwide population-based study","volume":"104","author":"Nielsen","year":"2025","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420949808","article-title":"Gender issues of antibody-mediated diseases in neurology: (NMOSD\/autoimmune encephalitis\/MG)","volume":"13","author":"Altintas","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1408606","article-title":"A systematic review of the epidemiology of pediatric autoimmune encephalitis: disease burden and clinical decision-making","volume":"15","author":"Santoro","year":"2024","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e200318","DOI":"10.1212\/NXI.0000000000200318","article-title":"Autoimmune encephalitis and paraneoplastic neurologic syndromes","volume":"11","author":"Kerstens","year":"2024","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jtcvs.2019.11.052","article-title":"A systematic review of paraneoplastic syndromes associated with thymoma: treatment modalities, recurrence, and outcomes in resected cases","volume":"160","author":"Zhao","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"123314","DOI":"10.1016\/j.jns.2024.123314","article-title":"Aging and infectious diseases in myasthenia gravis","volume":"468","author":"Bril","year":"2025","journal-title":"J Neurol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref23","article-title":"Occurrence and severity of myasthenic crisis in an unselected Turkish cohort of patients with myasthenia gravis","volume":"14","author":"Kose","year":"2023","journal-title":"Front Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.nmd.2021.11.014","article-title":"Spontaneous remission in juvenile myasthenia gravis: A cohort of 13 cases and review of the literature","volume":"32","author":"Arroyo","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1007\/s10072-024-07577-7","article-title":"Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion","volume":"45","author":"Mantegazza","year":"2024","journal-title":"Neurol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","article-title":"Factors affecting outcome in myasthenia gravis","volume":"54","author":"Andersen","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1237140","article-title":"Case report: seropositive myasthenia gravis complicated by limbic encephalitis positive for antibodies to AMPAR and Lgi1","volume":"14","author":"Nes","year":"2023","journal-title":"Front Neurol"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-023-03129-2","article-title":"AMPA and NMDA receptor antibody autoimmune encephalitis preceded by ocular myasthenia gravis: a case report","volume":"23","author":"Sch\u00e4fer","year":"2023","journal-title":"BMC Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01142","article-title":"Coexistence of autoimmune encephalitis and other systemic autoimmune diseases","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01343","article-title":"The muscle is not a passive target in myasthenia gravis","volume":"10","author":"Vilquin","year":"2019","journal-title":"Front Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31951-8","article-title":"Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma","volume":"13","author":"Yasumizu","year":"2022","journal-title":"Nat Commun"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","article-title":"Thymus and autoimmunity","volume":"43","author":"Marx","year":"2021","journal-title":"Semin Immunopathol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1046\/j.1468-1331.1998.540401.x","article-title":"The histomorphology of the thymus in late onset, non-thymoma myasthenia gravis","volume":"5","author":"Myking","year":"1998","journal-title":"Eur J Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.autrev.2013.03.002","article-title":"Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens","volume":"12","author":"Zisimopoulou","year":"2013","journal-title":"Autoimmun Rev"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00415-019-09544-1","article-title":"Epidemiology of paraneoplastic neurological syndromes: a population-based study","volume":"267","author":"Vogrig","year":"2020","journal-title":"J Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s00415-019-09461-3","article-title":"Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis","volume":"266","author":"Kimura","year":"2019","journal-title":"J Neurol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001053","article-title":"Thymoma and autoimmune encephalitis clinical manifestations and antibodies","volume":"8","author":"Guasp","year":"2021","journal-title":"Neurology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e70309","DOI":"10.1111\/ene.70309","article-title":"Beyond the surface: investigating the potential mechanisms of non-motor symptoms in myasthenia gravis","volume":"32","author":"Wang","year":"2025","journal-title":"Eur J Neurol"},{"key":"ref42","first-page":"50960-8966(21)00583-6","article-title":"Myasthenia gravis: do not forget the patient perspective","author":"Gilhus","year":"2021","journal-title":"J Neuromuscul Disord"},{"key":"ref43","article-title":"Advances in the genetics of myasthenia gravis: insights from cutting-edge neuroscience research","volume":"11","author":"Zheng","year":"2025","journal-title":"Front Med"},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53595-6","article-title":"Genome-wide meta-analysis of myasthenia gravis uncovers new loci and provides insights into polygenic prediction","volume":"15","author":"Braun","year":"2024","journal-title":"Nat Commun"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.667336","article-title":"Next-generation sequencing identifies extended HLA class I and II haplotypes associated with early-onset and late-onset myasthenia gravis in Italian, Norwegian, and Swedish populations","volume":"12","author":"Creary","year":"2021","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000646","article-title":"Treating muscle-specific kinase myasthenia gravis from the inside out","volume":"7","author":"Huijbers","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04994-2","article-title":"Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"102532","DOI":"10.1016\/j.autrev.2020.102532","article-title":"Comprehensive meta-analysis reveals an association of the HLA-DRB1*1602 allele with autoimmune diseases mediated predominantly by autoantibodies","volume":"19","author":"Chen","year":"2020","journal-title":"Autoimmun Rev"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/brain\/awae349","article-title":"Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts","volume":"148","author":"Binks","year":"2025","journal-title":"Brain"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-335960","article-title":"Clinical specificities and outcome of LGI1-antibody encephalitis according to age, sex and HLA","volume":"97","author":"Campetella","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15050518","article-title":"Anti-NMDA receptor encephalitis: A narrative review","volume":"15","author":"Padureanu","year":"2025","journal-title":"Brain Sci"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/ene.15238","article-title":"The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis","volume":"29","author":"Marcuse","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e114060","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PLoS One"},{"key":"ref54","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur J Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis - reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","article-title":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","volume":"49","author":"Romi","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.581097","article-title":"The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle","volume":"13","author":"Cetin","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"ref59","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13041136","article-title":"Transient neonatal myasthenia gravis as a common complication of a rare disease: A systematic review","volume":"13","author":"Lindroos","year":"2024","journal-title":"J Clin Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00415-019-09686-2","article-title":"Systematic review of the clinical spectrum of CASPR2 antibody syndrome","volume":"267","author":"Boyko","year":"2020","journal-title":"J Neurol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13311-022-01210-1","article-title":"Autoimmune neurological disorders with IgG4 antibodies: a distinct disease Spectrum with unique IgG4 functions responding to anti-B cell therapies","volume":"19","author":"Dalakas","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1346671","article-title":"Exploring the depths of IgG4: insights into autoimmunity and novel treatments","volume":"15","author":"\u00dcnl\u00fc","year":"2024","journal-title":"Front Immunol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"102594","DOI":"10.1016\/j.coi.2025.102594","article-title":"Pathogenic mechanisms of autoantibodies in neurological autoimmune diseases","volume":"95","author":"Fan","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"ref64","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1621045","article-title":"Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER","volume":"15","author":"Di","year":"2025","journal-title":"Front Oncol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.jtocrr.2024.100772","article-title":"Myasthenia gravis in patients treated with immune checkpoint inhibitors","volume":"6","author":"Alghabban","year":"2025","journal-title":"Jto Clinical Res. Rep."},{"key":"ref66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102936","article-title":"From ICI to ICU: a systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU)","volume":"136","author":"van Dijk","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548897","article-title":"Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota","volume":"16","author":"Vogrig","year":"2025","journal-title":"Front Immunol"},{"key":"ref68","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.13727","article-title":"Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders","volume":"8","author":"Fletcher","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Invest"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaf593","article-title":"Use of rituximab for fulminant and refractory cases of immune checkpoint inhibitor induced myocyte injury clinically presenting with features of myasthenia gravis: a case series","volume":"9","author":"Aziz","year":"2025","journal-title":"European Heart J. Case Rep."},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1671964","article-title":"Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report","volume":"16","author":"Lu","year":"2025","journal-title":"Front Immunol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501561","article-title":"A phase 3 trial of inebilizumab in generalized myasthenia gravis","volume":"392","author":"Nowak","year":"2025","journal-title":"N Engl J Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604174","article-title":"CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy","volume":"16","author":"Chinas","year":"2025","journal-title":"Front Immunol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02459-z","article-title":"Immunotherapy for autoimmune encephalitis","volume":"11","author":"Cheng","year":"2025","journal-title":"Cell Death Discov"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s13311-021-01178-4","article-title":"Antibody therapies in autoimmune encephalitis","volume":"19","author":"Smets","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref80","doi-asserted-by":"crossref","DOI":"10.1177\/08850666251409783","article-title":"Rituximab in the intensive care unit: a review of indications and clinical considerations","author":"Lincoln","year":"2025","journal-title":"J Intensive Care Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"106870","DOI":"10.1016\/j.msard.2025.106870","article-title":"Experience of bortezomib use in refractory autoimmune neurological disorders","volume":"105","author":"Popova","year":"2026","journal-title":"Mult Scler Relat Disord"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"106983","DOI":"10.1016\/j.imlet.2025.106983","article-title":"Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases","volume":"273","author":"Qin","year":"2025","journal-title":"Immunol Lett"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"123597","DOI":"10.1016\/j.lfs.2025.123597","article-title":"Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks","volume":"371","author":"Liu","year":"2025","journal-title":"Life Sci"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"e70280","DOI":"10.1111\/ene.70280","article-title":"Efgartigimod as a fast-acting add-on therapy in antibody-mediated autoimmune encephalitis","volume":"32","author":"Bi","year":"2025","journal-title":"Eur J Neurol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1605985","article-title":"Case report: therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis","volume":"16","author":"Watanabe","year":"2025","journal-title":"Front Immunol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13122975","article-title":"Efgartigimod for generalized myasthenia gravis and beyond: a narrative review of its pharmacological profile, clinical utility, and expanding applications","volume":"13","author":"Mansour","year":"2025","journal-title":"Biomedicine"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.neurol.2024.09.005","article-title":"The neurobiology and immunology of CASPR2-associated neurological disorders","volume":"180","author":"Joubert","year":"2024","journal-title":"Rev Neurol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1763320","article-title":"Case report: Thymoma-associated myasthenia gravis, myositis, myocarditis, and anti-GAD65 autoimmune encephalitis: a unique case of paraneoplastic polyautoimmunity","volume":"17","author":"Leiva-Murillo","year":"2026","journal-title":"Front Immunol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605214","article-title":"Common denominators in the Immunobiology of IgG4 autoimmune diseases: what do glomerulonephritis, pemphigus vulgaris, myasthenia gravis, thrombotic thrombocytopenic Purpura and autoimmune encephalitis have in common?","volume":"11","author":"Koneczny","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1812305\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:30:26Z","timestamp":1777005026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1812305\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":89,"alternative-id":["10.3389\/fneur.2026.1812305"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1812305","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1812305"}}